Medifast Reports Q3 Revenue of $72 Million, Guides Q4 EPS
Medifast reported Q3 2026 revenue of $72.0 million, down 19% year over year, and a net loss of $17.5 million, or $1.57 per share. It forecast Q4 2026 revenue of $55 million to $75 million and EPS of $0.00 to $0.25, with profitability expected.
Story updates
12:15:41 PM UTC
SquawkNews
MEDIFAST- FULL YEAR 2026 REVENUE EXPECTED $280 MLN TO $300 MLN\n
12:16:38 PM UTC
SquawkNews
MEDIFAST- FULL YEAR 2026 NON-GAAP LOSS PER SHARE EXPECTED $0.45 TO $0.7\n
12:16:58 PM UTC
SquawkNews
Medifast Q3 revenue falls on fewer active earning coaches Overview US metabolic health firm's Q3 rev
Medifast reported Q3 2026 revenue of $72.0M, down 19% YoY, and a net loss of $17.5M ($1.57/sh). It guided Q4 2026 revenue to $55M—$75M and EPS to $0.00—$0.25, and expects Q4 profitability.Material DetailsContext by AI AnalystThis is late confirmation of ongoing pressure from GLP-1 adoption and a sh…